Weight-loss pill alternatives to injectable anti-obesity medications are entering the market as pharmaceutical giants Novo Nordisk and Eli Lilly compete to supply oral treatments across Europe and the United States, according to recent industry reports. The shift from weekly injections to daily tablets marks a new phase in the commercial battle for the weight-management sector.
Novo Nordisk Leads European Rollout With Wegovy Pill
Danish pharmaceutical firm Novo Nordisk is currently leading the market race with its oral version of Wegovy, according to market data. The pill has already arrived in British pharmacies, and the European Commission approved the treatment last month, according to regulatory announcements. Germany will serve as the initial continental launchpad, while market entry in Switzerland remains pending. Sales figures show Novo Nordisk generated 400 million francs in revenue during the second quarter, outpacing its American rival.
Eli Lilly Prepares Orforglipron Market Entry
American drugmaker Eli Lilly is preparing its candidate, orforglipron, for international distribution. The company is currently awaiting regulatory decisions from roughly forty countries, including Switzerland, having secured approval only in the United Kingdom so far, according to company filings. Eli Lilly reported slightly under 80 million francs in revenue during the second quarter. Despite lagging in current sales volume, the American company’s pill offers a distinct dosing advantage over its competitor, as orforglipron can be taken independently of meals, whereas the oral Wegovy must be swallowed immediately upon waking before eating, drinking, or taking other medications.
Medical Experts Weigh Benefits and The Drawbacks of Oral Treatments
Endocrinologists at CHUV and HUG interviewed by RTS have expressed both enthusiasm and caution regarding the new oral medications. The specialists note that while pills offer simplicity and cost advantages over injections, their current weight-loss efficacy remains lower than injectable counterparts. Furthermore, doctors point out that patient resistance to needles is lower than commonly assumed, with those refusing injections remaining a distinct minority. Additionally, while injections are administered once a week, oral treatments require daily dosing, introducing potential adherence challenges alongside dietary considerations.
Did You Know? Oral anti-obesity treatments require daily administration, in contrast to injectable medications like Wegovy or Ozempic, which are typically taken just once a week.
Managing Health Risks and Preventing the Yo-Yo Effect
Medical professionals emphasize that weight-loss pills are not a miracle solution and carry the same potential risks as injectable treatments. According to endocrinologists from CHUV and HUG, these drugs suppress appetite by accelerating the feeling of satiation, leading patients to consume less food. This caloric reduction causes a loss of both body fat and muscle mass. To prevent muscle depletion and avoid the familiar “yo-yo” weight-regain effect seen with traditional diets, doctors stress that patients must combine the medication with proper nutrition and regular physical activity.
Pro Tip: Medical specialists advise pairing any anti-obesity drug regimen with structured physical activity and a balanced diet to preserve lean muscle mass during fat loss.
Frequently Asked Questions
Are weight-loss pills more effective than injections?
According to endocrinologists interviewed by RTS, the clinical efficacy of current oral treatments remains below that of injectable anti-obesity medications.
Which companies make the new weight-loss pills?
Novo Nordisk produces the oral version of Wegovy, while Eli Lilly manufactures orforglipron.
Do oral weight-loss treatments require dietary changes?
Yes. Medical experts stress that pills must be combined with a tailored diet and physical activity to prevent muscle loss and weight rebound.
Stay Updated on Health Innovations
Subscribe to our newsletter for the latest pharmaceutical updates and medical research developments.
Keep reading